| Venclexta (venetoclax) / Roche, AbbVie |
ACTRN12624000065594: ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain |
|
|
| Not yet recruiting | N/A | 100 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) | Acute Myeloid Leukaemia | | | | |
NCT07318662: Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML |
|
|
| Active, not recruiting | N/A | 224 | RoW | Venetoclax | Guangdong Provincial People's Hospital | MDS, CMML | 12/26 | 03/27 | | |
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy |
|
|
| Recruiting | N/A | 15 | Europe | Venetoclax, Azacitidine, Decitabine | Ospedale Maggiore Di Trieste | Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax | 09/20 | 09/20 | | |
NCT04230564: Acute Myeloid Leukemia Real World Treatment Patterns |
|
|
| Withdrawn | N/A | 0 | NA | azacitidine, venetoclax, glasdegib | Pfizer | Leukemia, Myeloid, Acute | 03/21 | 03/21 | | |
NCT06279572: Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy |
|
|
| Recruiting | N/A | 80 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Electronic Health Record Review | Mayo Clinic | Acute Myeloid Leukemia | 12/26 | 12/26 | | |
| Recruiting | N/A | 100 | Europe | Venetoclax, Venclyxto | Hannover Medical School | Acute Myeloid Leukemia | 11/21 | 11/25 | | |
NCT06536010: Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML |
|
|
| Recruiting | N/A | 50 | RoW | Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；, AZA 75mg/m2 on days 1-7, G-CSF: 50-600ug/day, starting on day 1 (adjusted based on WBC count of 10-25*10E9/L) | Yang Xiaotian | Acute Myeloid Leukemia | 07/26 | 07/28 | | |
NCT04655261: Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia |
|
|
| Terminated | N/A | 5 | RoW | | AbbVie | Chronic Lymphocytic Leukemia (CLL) | 11/21 | 11/21 | | |
NCT06162325: Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients |
|
|
| Enrolling by invitation | N/A | 45 | RoW | | Peking Union Medical College Hospital | Acute Myeloid Leukemia | 12/24 | 12/25 | | |
NCT07254611: Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations |
|
|
| Completed | N/A | 15 | Europe | | Fondazione IRCCS Policlinico San Matteo di Pavia | AML (Acute Myelogenous Leukemia | 02/23 | 02/23 | | |
DEVOTE, NCT03310190: Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice |
|
|
| Completed | N/A | 93 | Canada | | AbbVie | Chronic Lymphocytic Leukemia | 04/22 | 04/22 | | |
NCT06328179: Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. |
|
|
| Recruiting | N/A | 34 | RoW | Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；, Homoharringtoine, HHT 2 mg/m2，qd，d1-7, Etoposide 0.1 g，qd，d1-5, Cytarabine 100 mg/m2，qd，d1-7 | Huai'an First People's Hospital, Zhenjiang First People's Hospital, The First People's Hospital of Changzhou, The Affiliated Hospital of Xuzhou Medical University | Acute Myeloid Leukemia | 12/27 | 12/27 | | |
FORTE, NCT03873857: A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation |
|
|
| Completed | N/A | 71 | RoW | Venetoclax, Venclexta, ABT-199 | AbbVie | Chronic Lymphocytic Leukemia (CLL), Cancer | 09/22 | 09/22 | | |
NCT04198415: A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) |
|
|
| Completed | N/A | 4 | Japan | | AbbVie | Cancer, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) | 10/22 | 10/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Completed | N/A | 202 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 09/24 | 09/24 | | |
ChiCTR2300069069: Synergistic Effect of BCL-2 Inhibitor Venetoclax with Homoharringtonine on the Treatment of Early T-cell Precursor Acute lymphoblastic Leukemia and its Molecular Mechanism |
|
|
| Completed | N/A | 6 | | venetoclax combined with HAG regimen (Venetoclax+HHT+low-dose cytarabin+G-CSF) | The First Affiliated Hospital, Zhejiang University School of Medicine; the First Affiliated Hospital, Zhejiang University School of Medicine, fundings | Early T-cell precursor (ETP) acute lymphoblastic leukemia | | | | |
| No Longer Available | N/A | | NA | Navitoclax, ABT-263, Venetoclax, Venclexta, ABT-199, GDC-0199 | AbbVie | Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma | | | | |
NCT05053425: Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML |
|
|
| Recruiting | N/A | 30 | RoW | Venetoclax, ABT-199, Azacitidine, 5-Azacytidine, Cladribine, 2-CdA, Cytarabine, Ara-c, Idarubicin, Idamycin® | LanZhou University | Acute Myeloid Leukemia | 01/23 | 03/23 | | |
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy |
|
|
| Recruiting | N/A | 321 | Europe | Venetoclax | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia | 01/23 | 10/25 | | |
NCT05215405: Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL |
|
|
| No Longer Available | N/A | | US | Venetoclax, ABT-199, Navitoclax, ABT-263 | Kathleen Ludwig | Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma | | | | |
INNOVATE, NCT04253314: A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation |
|
|
| Completed | N/A | 51 | RoW | | AbbVie | Acute Myeloid Leukemia (AML) | 02/23 | 02/23 | | |
| Completed | N/A | 43 | RoW | Venetoclax | Sohag University | AML (Acute Myelogenous Leukemia) | 04/25 | 04/25 | | |
RALL-2016m, NCT06237192: MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients |
|
|
| Recruiting | N/A | 200 | RoW | blinatumomab for B-ALL, venetoclax for T-ALL | National Research Center for Hematology, Russia | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 09/26 | 09/27 | | |
| Available | N/A | | NA | Venetoclax, ABT-199, GDC-0199 | AbbVie | Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis, Plasma Cell Leukemia | | | | |
VENAURA, NCT06429670: Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory |
|
|
| Completed | N/A | 500 | Europe | | Hospices Civils de Lyon | Acute Myeloid Leukemia | 07/23 | 09/23 | | |
NCT06362031: A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review |
|
|
| Withdrawn | N/A | | NA | | AbbVie | Acute Myeloid Leukemia | 04/24 | 04/24 | | |
NCT06362044: A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan |
|
|
| Completed | N/A | 89 | Japan | | AbbVie | Chronic Lymphocytic Leukemia | 12/24 | 12/24 | | |
ChiCTR2000041509: The prospective, single arm, multicenter, and clinical trial of Dav regimen induction in the treatment of AML in adults |
|
|
| Not yet recruiting | N/A | 37 | | DAV regimen (daunorubicin 60mg/m2/d, qd, intravenous injection, d1~d3; cytarabine 100mg/m2/d, qd, intravenous injection, d1~d7, venetoclax 100mg d4, 200mg d5, 400mg d6 ~d11, qd, oral). During the induction treatment, the bone marrow was reviewed on d14 and d28. | The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine, Leading innovation and entrepreneurship team of Zhejiang Province | Acute myeloid leukemia | | | | |
NCT05262465: Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML |
|
|
| Recruiting | N/A | 300 | RoW | microtransplantation, HLA-mismatched donor peripheral stem cell infusion, DSI, Azacitidine, Demethylated drugs, Venetoclax, BCL/2 inhibitor | guomei | Adult Acute Myeloid Leukemia | 07/23 | 07/25 | | |
ELECTRIC, NCT05555979: A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom |
|
|
| Completed | N/A | 56 | Europe | | AbbVie | Chronic Lymphocytic Leukemia | 04/24 | 04/24 | | |
NCT05312112: Real World Outcomes Using Novel Agents for AML in the UK |
|
|
| Recruiting | N/A | 1000 | Europe | Venetoclax, Venclyxto, Gilteritinib, Xospata | Guy's and St Thomas' NHS Foundation Trust, King's College London | Acute Myeloid Leukemia | 10/23 | 10/23 | | |
NCT06131801: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution |
|
|
| Recruiting | N/A | 30 | US | 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. | Children's Hospital Medical Center, Cincinnati | Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma | 12/26 | 12/27 | | |
NCT06200220: Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia |
|
|
| Recruiting | N/A | 45 | Europe | Venetoclax | Poitiers University Hospital | Waldenstrom's Macroglobulinaemia Refractory | 12/23 | 12/25 | | |
ALLO-BEST, NCT04822766: A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia |
|
|
| Active, not recruiting | N/A | 24 | Europe | Hematopoietic stem cell transplantation, Best chemotherapy treatment | Assistance Publique - Hôpitaux de Paris | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
NCT06232694: Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML |
|
|
| Recruiting | N/A | 54 | RoW | Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;, Idarubicin (Idarubicin): 10-12mg/m2 on days 1 to 3; intravenous infusion, ;Cytarabine (Cytarabine): 100mg/m2 on days 1 to 7; intravenous infusion or subcutaneous injection., Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;, Cytarabine: 2g/m2 every 12 hours on day 1 to day 3; intravenous infusion;, utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT). | The First Affiliated Hospital with Nanjing Medical University, Huai'an First People's Hospital, Yancheng First People's Hospital | Acute Myeloid Leukemia | 12/27 | 12/27 | | |
NCT06192979: Optimize First-line Treatment for AL Amyloidosis With t (11; 14) |
|
|
| Recruiting | N/A | 41 | RoW | Daratumumab, Bortezomib, Dexamethasone, Venetoclax | Jin Lu, MD | Amyloidosis; Systemic, AL Amyloidosis | 12/25 | 06/26 | | |
ChiCTR2200056676: A multiple center and prospective clinical study of low dose of venetoclax combined with low dose of cytarabine and homoharringtonine in the treatment of newly diagnosed acute myeloid leukemia and myelodysplastic syndrome EB-2 over 60 years old or ineligible for intensive chemotherapy |
|
|
| Recruiting | N/A | 30 | | low-dose veneclax combined with low-dose cytarabine and homoharringtonine | First Hospital of Tsinghua University; First Hospital of Tsinghua University, self-service | acute myeloid leukemia and myelodysplastic syndrome EB-2 | | | | |
| Recruiting | N/A | 120 | RoW | Ivosidenib,Venetoclax,gilteritinib,Selinexor | Institute of Hematology & Blood Diseases Hospital, China | AML, Refractory, Relapsed | 01/26 | 06/26 | | |
ChiCTR2200058734: A prospective, open-label, single-arm, single-arm clinical trial of HCV regimen (decitabine/azacytidine + Cladribine + Venetoclax) in the treatment of relapsed/refractory childhood AML |
|
|
| Not yet recruiting | N/A | 60 | | Venetoclax+azacitidine/decitabine+cladribine | Children's Hospital of Soochow University; Children's Hospital of Soochow University, Suzhou government and Children's Hospital of Soochow University | acute myeloid leukemia | | | | |
APL, NCT06450145: Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant |
|
|
| Recruiting | N/A | 15 | RoW | interferon α-2b, arsenic trioxide, venetoclax | Zhejiang Provincial People's Hospital, First Affiliated Hospital of Zhejiang University | Tumour | 12/25 | 12/25 | | |
| Recruiting | N/A | 120 | RoW | Ivosidenib, Gilteritinib, Venetoclax, Avapritinib, Daunorubicin, Cytarabine, Idarubicin, MTZ, HHT, Azacitidine | Institute of Hematology & Blood Diseases Hospital, China | AML, Adult | 05/26 | 04/28 | | |
NCT06301425: MRD Response-adapted Allo-HSCT for Adverse-risk AML |
|
|
| Recruiting | N/A | 178 | RoW | Intervention group, Control group | Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, Anhui Provincial Hospital | Acute Myeloid Leukemia | 05/27 | 05/28 | | |
ChiCTR2500102899: A retrospective study: venetoclax-based therapy for patients with myeloid sarcoma |
|
|
| Completed | N/A | 14 | | None | The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University, Self-financing | Myeloid sarcoma | | | | |
NCT05471700: Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients |
|
|
| Completed | N/A | 40 | RoW | Azacitidine, 5-Azacitidine, 5-aza, Venetoclax, Venclexta, Venclyxto | Zhujiang Hospital | Leukemia, Myeloid, Acute | 04/23 | 04/23 | | |
NCT06481228: Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL |
|
|
| Recruiting | N/A | 82 | RoW | CAR-T cells, Venetoclax, Olverembatinib | Institute of Hematology & Blood Diseases Hospital, China | Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult | 06/26 | 06/28 | | |
NCT06481241: Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL |
|
|
| Recruiting | N/A | 77 | RoW | CAR-T cells, Venetoclax, Selective inhibitor of B-cell lymphoma 2 (Bcl-2) | Institute of Hematology & Blood Diseases Hospital, China | Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult | 06/26 | 06/28 | | |
NCT06390306: The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP |
|
|
| Recruiting | N/A | 30 | RoW | Ponatinib, Azacitidine, Venetoclax, Olverembatinib | Peking University People's Hospital, Wuhan Union Hospital, China, Henan Cancer Hospital, Zhejiang University, Peking Union Medical College, Nanfang Hospital, Southern Medical University, Beijing Chuiyangliu Hospital | Chronic Myeloid Leukemia | 12/26 | 12/27 | | |
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine |
|
|
| Recruiting | N/A | 230 | Europe | | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult | 12/24 | 03/25 | | |
ChiCTR2400090821: Clinical efficacy and adverse reactions analysis of combination therapy of Venetoclax and hypomethylated drugs in the treatment of acute myeloid leukemia: a retrospective multi-center clinical study in the real world. |
|
|
| Completed | N/A | 181 | | No interventions; No interventions | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, self-financing | Acute myeloid leukemia | | | | |
ChiCTR2200063804: Venetoclax, azacitidine, combined with low-dose cytarabine in treatment-naive, elderly or unfit patients with acute myeloid leukemia |
|
|
| Recruiting | N/A | 65 | | Venetoclax, azacitidine, combined with low-dose cytarabine | Second Affiliated Hospital, Army Medical University; Second Affiliated Hospital, Army Medical University, Patients pay for medical care | Acute meyloid leukemia | | | | |
NCT06386302: Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia |
|
|
| Recruiting | N/A | 184 | RoW | Chidamide, Venetoclax, azacitidine | Institute of Hematology & Blood Diseases Hospital, China | AML, Acute Myeloid Leukemia | 12/27 | 12/27 | | |
ChiCTR2100050272: Study on the Safety and Efficacy of Elderly High-risk MDS/AML Patients Undergoing Hematopoietic Stem Cell Transplantation with Venetoclax Combined with Dicitabine-based Preconditioning Regimen |
|
|
| Not yet recruiting | N/A | 21 | | Venetoclax Combined Descitabine Preconditioning Regimen | Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Self-financed | Myelodysplastic syndrome/acute myeloid leukemia | | | | |
| Recruiting | N/A | 36 | RoW | cladribine, cytarabine,venetoclax | The First Affiliated Hospital of Soochow University, Jining Medical University, The Second People's Hospital of Huai'an, The First Affiliated Hospital of Bengbu Medical University, Northern Jiangsu People's Hospital, Affiliated Hospital of Nantong University, Suzhou Hospital of Traditional Chinese Medicine | Acute Lymphoblastic Leukemia | 10/26 | 10/26 | | |
| Completed | N/A | 20 | Europe | Pharmacokinetic sampling, Vital status determination, Toxicity assessments, Venetoclax and azacitidine combination | Centre Hospitalier Universitaire de Nice | Acute Myeloid Leukemia | 09/24 | 03/25 | | |
VEN-AML, NCT07254312: Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission. |
|
|
| Recruiting | N/A | 14 | Europe | | Fondazione IRCCS Policlinico San Matteo di Pavia | AML (Acute Myelogenous Leukemia | 04/26 | 04/26 | | |
NCT06643962: Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy |
|
|
| Recruiting | N/A | 83 | RoW | Venetoclax, Bcl-2 inhibitors, Idarubincin, IDA, Cytarabine, Ara-C | Affiliated Hospital of Nantong University | Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute | 12/25 | 10/27 | | |
ChiCTR2100053516: A prospective, single-arm, multicenter, exploratory clinical trial of the efficacy and safety of VHAA regimen induction therapy in adults with untreated AML |
|
|
| Recruiting | N/A | 37 | | VHAA regimen (HHT 2mg/m2/d, qd, intramuscular injection, d1~d5; cytarabine 100mg/m2/d, q12h, subcutaneous injection, d1~d5, aclarithromycin 12mg/m2/d, Intravenous injection, d1~d5, venetoclax 100mg d2, 200mg d3, 300mg d4~d10, qd, oral) | First Affiliated Hospital of Zhejiang University School of Medicine; First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Hematological Disorders | Acute myeloid leukemia (AML) | | | | |
NCT05863845: Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL |
|
|
| Not yet recruiting | N/A | 52 | NA | Venetoclax, Carmustine, Cytarabine, Etoposide, Melphalan, Hematopoietic Cell Transplantation | Ruijin Hospital | Diffuse Large B Cell Lymphoma | 11/24 | 11/25 | | |
ChiCTR2200058095: Single center, open, non randomized, single arm clinical trial of daretouximab and venetoclax combined with cage regimen in the treatment of refractory / recurrent adult T-lymphoblastic leukemia / lymphoma |
|
|
| Not yet recruiting | N/A | 20 | | CAGE regimen with daletuzumab and Venetoclax | Beijing Boren Hospital Co., Ltd.; Beijing Boren Hospital, self-funded | Refractory / recurrent adult T lymphoblastic leukemia / lymphoma | | | | |
NCT07117422: Venetoclax-Decitabine in Untreated Elderly/Unfit AML |
|
|
| Recruiting | N/A | 39 | RoW | VEN + DEC | The Second Hospital of Hebei Medical University, Handan First Hospital | AML, Adult | 01/26 | 01/27 | | |
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration |
|
|
| Active, not recruiting | N/A | 80 | US | Peripheral blood draw, Bone marrow aspirate, Buccal swab | Washington University School of Medicine, Notable Labs | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 01/26 | 01/26 | | |
NCT06045819: Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX) |
|
|
| Recruiting | N/A | 100 | Europe | Blood sampling for venetoclax drug dosage (venous puncture), Biological: Capillary Blood sampling for venetoclax drug dosage with Volumetric Absorptive Microsampling (VAMS™) technology with Mitra® device (CE-IVD /IVDR), Biological: Blood sampling for azole antifungal drug dosage (venous puncture) | University Hospital, Caen | Adult Acute Myeloid Leukemia | 02/25 | 01/26 | | |
NCT06697327: Daunorubicin + Cytarabine + Venetoclax in de Novo AML |
|
|
| Enrolling by invitation | N/A | 94 | RoW | (Daunorubicin, Cytarabine, Venetoclax), (Daunorubicin, Cytarabine) | Anhui Medical University, The First Affiliated Hospital of Anhui Medical University | Leukemia, Myeloid, Acute, Acute Myeloid Leukemia | 08/25 | 08/26 | | |
NCT06841952: Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia |
|
|
| Not yet recruiting | N/A | 158 | RoW | ATRA+Venetoclax+Azacitidine, Chemotherapy drug | The First Affiliated Hospital of Soochow University | AML, Adult | 12/28 | 12/30 | | |
NCT04813263: Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia |
|
|
| Completed | N/A | 424 | Japan | | AbbVie | Acute Myeloid Leukemia (AML) | 04/24 | 04/24 | | |
VALOR, NCT05215639: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets |
|
|
| Completed | N/A | 120 | Europe | | AbbVie | Acute Myeloid Leukemia | 11/25 | 11/25 | | |
ChiCTR2200058248: A observational clinical study valuating the effectiveness and safety of venetoclax combined with azacytidine and harringtonolide in the treatment of newly diagnosed elderly acute myeloid leukemia patients |
|
|
| Not yet recruiting | N/A | | | | Shanxi Bethune Hospital of Shanxi Medical University; Shanxi Bethune Hospital of Shanxi Medical University, Key Research and Development Program of Shanxi Province (201903D321133), Scientific Research Project for Adolescents of Shanxi Province (20210302124037) | acute myeloid leukemia (non-APL) | | | | |
NCT06580106: Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML |
|
|
| Recruiting | N/A | 50 | US | Biospecimen samples | Wake Forest University Health Sciences, Atrium Health Levine Cancer Institute, Swim Across America | Leukemia, Myeloid, Acute | 07/27 | 01/30 | | |
PMID38293753: Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma |
|
|
| Not yet recruiting | N/A | 40 | NA | Gazyva (obinutuzumab) - Roche, Biogen, Venclexta (venetoclax) - Roche, AbbVie | Massachusetts General Hospital | chronic lymphocytic leukemia or small lymphocytic lymphoma | | | | |
NCT05909293: Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission |
|
|
| Recruiting | N/A | 100 | RoW | Venclexta 100 MG Oral Tablet, Granulocyte colony-stimulating factor (G-CSF), Interleukin-11 (IL-11), Antibiotics, Blood products, Antiemetics | The First Affiliated Hospital with Nanjing Medical University, Huai'an First People's Hospital, Yancheng First People's Hospital | Acute Myeloid Leukemia | 05/25 | 05/28 | | |
NCT03680677: Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies |
|
|
| Recruiting | N/A | 20 | US | Bone Marrow or Peripheral Blood Graft (BMT), Cancer-directed Therapy or Best Supportive Care, Frailty Assessment | Abramson Cancer Center at Penn Medicine | Leukemia, Acute, MDS | 06/26 | 11/26 | | |
ChiCTR2500097988: H(E)AG Regimen Combined with Venetoclax and Azacitidine for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter, Retrospective Cohort Study |
|
|
| Recruiting | N/A | 100 | | None; None | The second affiliated hospital of the army medical university; The second affiliated hospital of the army medical university, without Research Funding | Acute Myeloid Leukemia | | | | |
NCT07187505: Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia |
|
|
| Active, not recruiting | N/A | 28 | RoW | Venetoclax, Venclexta, All-trans retinoic acid, Tretinoin, Vesanoid, Arsenic Trioxide (ATO), Trisenox | Anhui Medical University, The First Affiliated Hospital of Anhui Medical University | Acute Promyelocytic Leukemia (APL) | 07/27 | 07/27 | | |
ChiCTR2500097318: Azacitidine, Venetoclax Combined with Dexamethasone for the Treatment of Refractory and Relapsed Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 35 | | All patients were treated with azacitidine combined with venetoclax and dexamethasone azacitidine (AZA): 75 mg/m2, days 1-7 Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg on days 3-28 Dexamethasone (DXM): 20 mg on days 1-4 and 11-14 | The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, self-financing | Acute Lymphoblastic Leukemia | | | | |
Ven-BUCY, NCT07183878: Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT ( Study) |
|
|
| Recruiting | N/A | 138 | RoW | Venetoclax, ABT-199, Venclexta, None-placebo | First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital of Zhengzhou University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital, The Children's Hospital of Zhejiang University School of Medicine, Ruijin Hospital North Shanghai Jiao Tong University School of Medicine | Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes | 08/27 | 08/28 | | |
| Recruiting | N/A | 80 | RoW | SC cytarabine +Venetoclax, Venclexta | Sohag University | Acute Myeloid Leukaemia (AML) | 09/26 | 09/27 | | |
MOIRAI, 2023-510294-34-00: A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ ) |
|
|
| Recruiting | N/A | 109 | EU | Gazyva (obinutuzumab) - Roche, Biogen, Venclexta (venetoclax) - Roche, AbbVie, Jaypirca (pirtobrutinib) - Eli Lilly | University Of Cologne, Eli Lilly & Co. ; F. Hoffmann-La Roche Ltd.; AbbVie Inc. | chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) | | | | |
NCT04178317: A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice |
|
|
| Completed | N/A | 14 | RoW | | AbbVie | Cancer, Chronic Lymphocytic Leukemia (CLL) | 08/25 | 08/25 | | |
NCT06991920: Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage |
|
|
| Not yet recruiting | N/A | 50 | NA | Blinatumomab, Venetoclax | Institute of Hematology & Blood Diseases Hospital, China | Adult ALL, MPAL | 04/30 | 04/32 | | |
| Not yet recruiting | N/A | 52 | | low-dose HHT combined with Venetoclax sequential allogeneic hematopoietic stem cell transplantation | The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, self-financing | R/R AML and high-risk MDS | | | | |
NCT06066242: Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy |
|
|
| Recruiting | N/A | 90 | RoW | Different induction chemotherapy regimens | Institute of Hematology & Blood Diseases Hospital, China | Acute Myeloid Leukemia | 10/25 | 10/25 | | |
NCT07236931: Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells |
|
|
| Not yet recruiting | N/A | 71 | RoW | the XAB regimen | Donghua Zhang | AML (Acute Myeloid Leukemia) | 10/27 | 10/28 | | |
NCT04826523: Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML) |
|
|
| Completed | N/A | 150 | RoW | | AbbVie | Acute Myeloid Leukemia (AML) | 10/25 | 10/25 | | |
ESVECO, NCT05587049: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia |
|
|
| Recruiting | N/A | 70 | RoW | | AbbVie | Acute Myeloid Leukemia | 11/26 | 11/26 | | |
| Recruiting | N/A | | NA | emavusertib (CA-4948) - Curis, Dr. Reddy’s | Curis Inc. | Acute myeloid leukemia | | | | |
P17-132, NCT03342144: Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting |
|
|
| Recruiting | N/A | 500 | Europe | | AbbVie | Chronic Lymphocytic Leukemia (CLL) | 12/30 | 12/30 | | |
NCT04616274: Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 500 | RoW | Venetoclax | National Taiwan University Hospital | Chronic Lymphocytic Leukemia | 12/25 | 12/25 | | |
NCT04613622: Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia |
|
|
| Recruiting | N/A | 500 | RoW | Venetoclax | National Taiwan University Hospital | Acute Myeloid Leukemia | 12/25 | 12/25 | | |
ChiCTR2300079066: A clinical study of mitoxantrone liposome combined with venetoclax and azacitidine in the treatment of relapsed/refractory AML patients who are intolerant to intensive chemotherapy |
|
|
| Not yet recruiting | N/A | 12 | | Mitoxantrone hydrochloride liposome injection | The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University, self-financing | relapsed and refractory acute lymphoblastic leukemia | | | | |
ChiCTR2400089805: A exploratory study to evaluate the efficacy and safety of interferon-α combined with ATO in the treatment of arsenic-resistant acute promyelocytic leukemia |
|
|
| Not yet recruiting | N/A | 15 | | For patients with arsenic-resistant relapse, interferon α-2b injection was added on the basis of conventional treatment | Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital, National Key Research and Development Program of China | Arsenic-resistant acute promyelocytic leukemia | | | | |
ChiCTR2500098311: Multicenter, Single-Arm, Bidirectional Cohort Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined with Cytarabine, Etoposide, Dexamethasone +/- Venetoclax (MAED+/-Ven Regimen) in the Treatment of Mixed Phenotype Acute Leukemia |
|
|
| Not yet recruiting | N/A | 32 | | Mitoxantrone Hydrochloride Liposome Injection Combined with Cytarabine, Etoposide, Dexamethasone +/- Venetoclax | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Mixed Phenotype Acute Leukemia | | | | |
NCT07319793: Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT |
|
|
| Not yet recruiting | N/A | 200 | NA | Prophylactic DLI, Preemptive DLI | Peking University People's Hospital | Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS) | 01/27 | 06/28 | | |
EUREKA-VEN, NCT07243483: Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia |
|
|
| Recruiting | N/A | 100 | Europe | Pharmacokinetic dosages of venetoclax | Centre Leon Berard, Fédération Leucémie Espoir | Acute Myeloid Leukemia | 01/28 | 01/29 | | |
ChiCTR2500101192: Efficacy and safety study of Venetoclax in combination with high dose of Decitabine and Homoharringtonine(DEC3-VEN-HHT)as therapy for newly diagnosed patient acute myeloid leukemia with RUNX1 / RUNX1TI, CBFB/MYH11 mutation( a phase 2, multicenter, single-arm trial) |
|
|
| Recruiting | N/A | 40 | | Venetoclax in combination with high dose of Decitabine and Homoharringtonine (DEC3-VEN-HHT) as therapy | Tai'an City Central Hospital; The Affiliated Tai'an City Central Hospital of Qingdao University, None | Newly diagnosed patient acute myeloid leukemia with RUNX1 / RUNX1TI, CBFB/MYH11 mutation | | | | |
ChiCTR2300074726: Study of the TBFC/V regimen (thiotepa combined with busulfan, fludarabine and cyclophosphamide (TBFC) or thiotepa combined with busulfan, fludarabine and venetoclax (TBFV) in a pretreatment regimen for allogeneic haematopoietic stem cell transplantation |
|
|
| Recruiting | N/A | 30 | | None; None | The First Affiliated Hospital of Ningbo University; Department of Hematology, self-funding | Malignant hematology disease | | | | |
VERO, NCT06058741: A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy |
|
|
| Active, not recruiting | N/A | 150 | Europe | | AbbVie | Acute Myeloid Leukemia | 11/26 | 11/26 | | |
ChiCTR2500105011: Venetoclax combined with half-dose CMG regimen (cytarabine, mitoxantrone liposomes, and granulocyte colony-stimulating factor) for the treatment of newly diagnosed patients who are intolerant to intensive chemotherapy Single-center, exploratory clinical study on acute myeloid leukemia |
|
|
| Recruiting | N/A | 20 | | Undergo induction therapy with the VCMG regimen | Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Beijing Hisco Clinical Oncology Research Foundation | Acute myeloid leukemia | | | | |
VERONE, NCT03415035: Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | N/A | 269 | Europe | | AbbVie | Cancer - Chronic Lymphocytic Leukemia | 06/26 | 06/26 | | |
NCT04159779: A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece |
|
|
| Active, not recruiting | N/A | 180 | Europe | | AbbVie | Chronic Lymphocytic Leukemia | 06/26 | 06/26 | | |
LIVEN, NCT05424562: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada |
|
|
| Active, not recruiting | N/A | 210 | Canada | | AbbVie | Acute Myeloid Leukemia | 03/27 | 03/27 | | |
